BASELINE CHARACTERISTICS OF PATIENTS INITIATING IXEKIZUMAB, SECUKINUMAB OR A TUMOUR NECROSIS FACTOR INHIBITOR BY COUNTRY IN THE 24-MONTH PROSPECTIVE PSORIATIC ARTHRITIS OBSERVATIONAL STUDY OF PERSISTENCE OF TREATMENT - PRO-SPIRIT

被引：0
|
作者：
Gullick, Nicola [1 ]
Sheesh, Mohamed [2 ]
Laedermann, Cedric [2 ]
Ngantcha, Marcus [2 ]
Gittens, Beatrice [2 ]
Ng, Khai Jing [2 ]
Tillett, William [3 ]
Morel, Jacques [4 ,5 ]
Lubrano, Ennio [6 ,7 ]
Alten, Rieke [8 ]
Kristensen, Lars Erik [9 ]
Chandran, Vinod [10 ,11 ]
Martinez-Ferrer, Angels [12 ]
Kirkham, Bruce [13 ]
机构：
[1] Univ Warwick, Rheumatol, Coventry, W Midlands, England
[2] Eli Lilly & Co, Rheumatol, Indianapolis, IN USA
[3] Univ Bath, Dept Life Sci, Bath, Avon, England
[4] CHU Montpellier, Rheumatol, Montpellier, France
[5] Univ Montpellier, Montpellier, France
[6] Univ Molise, Acad Rheumatol Unit, Dipartimento Med & Sci Salute Vincenzo Tiberio, Campobasso, Italy
[7] KU Leuven Univ, Dept Dev & Regenerat, Skeletal Biol & Engn Res Ctr, Louvain, Belgium
[8] Univ Med Berlin, Dept Internal Med & Rheumatol, Schlosspark Klin, Berlin, Germany
[9] Univ Copenhagen, Parker Inst, Bispebjerg & Frederiksberg Hosp, Copenhagen, Denmark
[10] Univ Hlth Network, Schroeder Arthrit Inst, Krembil Res Inst, Toronto, ON, Canada
[11] Univ Toronto, Dept Med, Div Rheumatol, Toronto, ON, Canada
[12] Univ Valencia, Hosp Univ Doctor Peset, Valencia, Spain
[13] Guys & St Thomas NHS Fdn Trust, Dept Rheumatol, London, England
来源：
RHEUMATOLOGY | 2024年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E066
引用
收藏
页码：I153 / I154
页数：2
相关论文
共 24 条
  • [1] Baseline characteristics of patients initiating ixekizumab, secukinumab or a tumour necrosis factor inhibitor by country in the 24-month Prospective Psoriatic Arthritis Observational Study of Persistence of Treatment - PRO-SPIRIT
    Gullick, Nicola
    Sheesh, Mohamed
    Laedermann, Cedric
    Ngantcha, Marcus
    Gittens, Beatrice
    Ng, Khai Jing
    Tillett, William
    Morel, Jacques
    Lubrano, Ennio
    Alten, Rieke
    Kristensen, Lars Erik
    Chandran, Vinod
    Martinez-Ferrer, Angels
    Kirkham, Bruce
    RHEUMATOLOGY, 2024, 63
  • [2] A 24-MONTH PROSPECTIVE PSORIATIC ARTHRITIS OBSERVATIONAL STUDY OF PERSISTENCE OF TREATMENT (PRO-SPIRIT) - INTERIM ANALYSIS OF BASELINE CHARACTERISTICS
    Morel, J.
    Dagna, L.
    Joven-Ibanez, B.
    Holzkaemper, T.
    El Baou, C.
    Unger, L.
    Semeraro, A.
    Gullick, N.
    Treuer, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1578 - 1578
  • [3] STUDY DESIGN AND FULL BASELINE SAMPLE CHARACTERISTICS OF PATIENTS FROM THE 24-MONTH MULTINATIONAL PROSPECTIVE PSORIATIC ARTHRITIS OBSERVATIONAL STUDY OF PERSISTENCE OF TREATMENT (PRO-SPIRIT)
    Morel, J.
    Lubrano, E.
    Tillett, W.
    Alten, R.
    Kristensen, L. E.
    Chandran, V.
    Treuer, T.
    Burke, J.
    Martinez-Ferrer, A.
    Holzkaemper, T.
    Gullick, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1786 - 1787
  • [4] A 24-MONTH PROSPECTIVE PSORIATIC ARTHRITIS OBSERVATIONAL STUDY OF PERSISTENCE OF TREATMENT - INTERIM ANALYSIS OF BASELINE CHARACTERISTICS
    Morel, Jacques
    Dagna, Lorenzo
    Ibanez, Beatriz Joven
    Holzkaemper, Thorsten
    El Baou, Celine
    Unger, Leonore
    Semeraro, Angelo
    Gullick, Nicola
    Treuer, Tamas
    RHEUMATOLOGY, 2023, 62
  • [5] Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study
    Ramonda, Roberta
    Lorenzin, Mariagrazia
    Carriero, Antonio
    Chimenti, Maria Sole
    Scarpa, Raffaele
    Marchesoni, Antonio
    di Scorpaniello, Ennio Lubrano
    Salvarani, Carlo
    Cauli, Alberto
    Semeraro, Angelo
    Santo, Leonardo
    Ortolan, Augusta
    Doria, Andrea
    Fracassi, Elena
    Virelli, Giulia
    Masia, Marco
    Fanizzi, Rosalinda
    Visalli, Elisa
    Amato, Giorgio
    Carletto, Antonio
    Foti, Rosario
    RMD OPEN, 2021, 7 (01):
  • [6] Predicts factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients
    Fautrel, Bruno
    Belhassen, Manon
    Hudry, Christophe
    Woronoff-Lemsi, Marie-Christine
    Levy-Bachelot, Laurie
    Van Ganse, Eric
    Tubach, Florence
    JOINT BONE SPINE, 2020, 87 (03) : 267 - 269
  • [7] Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients
    Fautrel, Bruno
    Belhassen, Manon
    Hudry, Christophe
    Woronoff-Lemsi, Marie-Christine
    Levy-Bachelot, Laurie
    Van Ganse, Eric
    Tubach, Florence
    JOINT BONE SPINE, 2020, 87 (02) : 137 - 139
  • [8] A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITOR(S)
    Nash, P.
    Kirkham, B.
    Okada, M.
    Rahman, P.
    Combe, B.
    Adams, D. H.
    Kerr, L. N.
    Lee, C. H.
    Shuler, C. L.
    Genovese, M. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 135 - 135
  • [9] Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
    Saad, Amr A.
    Ashcroft, Darren M.
    Watson, Kath D.
    Hyrich, Kimme L.
    Noyce, Peter R.
    Symmons, Deborah P. M.
    ARTHRITIS RESEARCH & THERAPY, 2009, 11 (02)
  • [10] Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
    Amr A Saad
    Darren M Ashcroft
    Kath D Watson
    Kimme L Hyrich
    Peter R Noyce
    Deborah PM Symmons
    Arthritis Research & Therapy, 11
123